# Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

> **NCT00332709** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 83 (actual)

## Conditions studied

- Osteoporosis
- Postmenopausal

## Interventions

- **DRUG:** Letrozole
- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00332709
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2011-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332709, "Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00332709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*